NCT07130695View on ClinicalTrials.gov

Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2029

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Olutasidenib Investigational Agent Administration

Twice daily olutasidenib maintenance therapy

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

Sponsors

Collaborators (1)

Rigel Pharmaceuticals

All Listed Sponsors

collaborator

Rigel Pharmaceuticals

INDUSTRY

lead

Virginia Commonwealth University

OTHER